CanSino: Recombinant Novel Coronavirus Vaccine Approved for Sequential Booster Immunizations – Xinhua English.news.cn

Securities Times e Company News, CanSino (688185) announced on the evening of February 21 that the National Health Commission has begun to deploy sequential booster immunizations for the new crown vaccine. Up to now, the company’s recombinant novel coronavirus vaccine (type 5 adenovirus vector) (trade name: Keweisha®) has obtained conditional marketing approval in China and emergency use authorization in many overseas countries. After the product is approved for sequential booster immunization, if the relevant state departments increase its purchases in the future, it will have a positive impact on the company’s performance.